Lymphoma, Primary Effusion - 14 Studies Found
Recruiting |
: Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma :
: |
Recruiting |
: Study to Evaluate Safety and Tolerability of XmAb13676 in Patients With CD20-expressing Hematologic Malignancies :
|
Recruiting |
: 124I-FIAU Imaging in EBV and KSHV Associated Cancers :
: |
NOT_YET_RECRUITING |
: Daratumumab for Relapsed/Refractory Primary Effusion Lymphoma : : 2024-05-13 : Daratumumab SC (daratumumab and hyaluronidase) is administered subcutaneously (SC) as 1800 mg/30,000 units weekly for a total of 8 weeks (8 doses |